← Back to homepage
How investors killed AstraZeneca’s $400bn megadeal
Sources
2
Coverage
Limited spectrum
Sentiment
0.00
◀ Left 0%Centre 100%Right 0% ▶
How we rate bias →This story is currently only covered by 2 sources from a limited part of the political spectrum. NewsDeck will update this page automatically if other outlets pick up the story.
NewsDeck Poll
Do you think this story is being covered fairly across the political spectrum?
Loading…
Left
(0)
No coverage from this perspective yet
Centre
(2)
FT UK
How investors killed AstraZeneca’s $400bn megadeal
Tie-up with US rival Bristol Myers would have marked return to big pharma mergers
11 Aug, 05:59
City AM
Astrazeneca explores $400bn megadeal with US rival
Astrazeneca is exploring a $400bn (£300bn) merger with US rival Bristol Myers Squibb, in a deal that would create one of the world’s largest pharmaceutical groups. The FTSE 100 giant has held talks with the US group in recent months about a possible tie-up, according to reports in the Financial Times. Talks could lead to a [...]
3 Aug, 06:36
Right
(0)
No coverage from this perspective yet